Angiotensin II (Ang II) activates cytosolic Ca 2ϩ -dependent phospholipase A 2 (cPLA 2 ), phospholipase D (PLD), p38 mitogen-activated protein kinase (MAPK), epidermal growth factor receptor (EGFR) and Akt in vascular smooth muscle cells (VSMC). This study was conducted to investigate the relationship between Akt activation by Ang II and other signaling molecules in rat VSMC. Ang II-induced Akt phosphorylation was significantly reduced by the PLD inhibitor 1-butanol, but not by its inactive analog 2-butanol, and by brefeldin A, an inhibitor of the PLD cofactor ADP-ribosylation factor, and in cells infected with retrovirus containing PLD 2 siRNA or transfected with PLD 2 antisense but not control LacZ or sense oligonucleotide. Diacylglycerol kinase inhibitor II diminished Ang II-induced and diC8-phosphatidic acid (PA)-increased Akt phosphorylation, suggesting that PLD-dependent Akt activation is mediated by PA. Ang II-induced EGFR phosphorylation was inhibited by 1-butanol and PLD 2 siRNA and also by cPLA 2 siRNA. In addition, the inhibitor of arachidonic acid (AA) metabolism 5,8,11,14-eicosatetraynoic acid (ETYA) reduced both Ang II-and AAinduced EGFR transactivation. Furthermore, ETYA, cPLA 2 antisense, and cPLA 2 siRNA attenuated Ang II-elicited PLD activation. p38 MAPK inhibitor SB202190 [4-(4-flurophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] reduced PLD activity and EGFR and Akt phosphorylation elicited by Ang II. Pyrrolidine-1, a cPLA 2 inhibitor, and cPLA 2 siRNA decreased p38 MAPK activity. These data indicate that Ang II-stimulated Akt activity is mediated by cPLA 2 -dependent, p38 MAPK regulated PLD 2 activation and EGFR transactivation. We propose the following scheme of the sequence of events leading to activation of Akt in VSMC by Ang II: Ang II3cPLA 2 3 AA3p38 MAPK3 PLD 2 3 PA3 EGFR3 Akt.
mTOR, which regulate cell survival, cell cycle, glucose metabolism, angiogenesis, vasomotor tone, and protein synthesis (Shiojima and Walsh, 2002) .
Akt has also been implicated in the action of Ang II to promote vascular smooth muscle cells (VSMC) proliferation and growth. Ang II stimulates Akt activity through the angiotensin type 1 receptor (AT 1 R) in VSMC (Takahashi et al., 1999) . Ang II activates cytosolic Ca 2ϩ -dependent phospholipase A 2 (cPLA 2 ) and releases arachidonic acid (AA) via activation of AT 1 R (Rao et al., 1994; Muthalif et al., 1998) . AA and its metabolite(s) 5(S)-and 12(S)-hydroxyeicosatetraenoic acid generated via lipoxygenase have been shown to increase Akt activity in VSMC or other cell types (Szekeres et al., 2002; Zeng et al., 2002) . Also, Ang II increases phospholipase D (PLD) activity in VSMC through AT 1 R (Freeman and Tallant, 1994) . PLD has been reported to be involved in Akt activation caused by sphingosine-1-phosphate in Chinese hamster ovary cells overexpressing endothelial differentiation gene (EDG 3 ) receptor (Banno et al., 2001) . It is not known whether PLD is also involved in Ang II-induced Akt activation in VSMC. Activation of PLD by Ang II is dependent upon cPLA 2 activity in rabbit VSMC (Parmentier et al., 2001b) . AA production from PLA 2 has been shown to increase Akt activity in mesangial cells and VSMC (Gorin et al., 2001; Neeli et al., 2003) . Therefore, it is possible that Ang II causes Akt activation in rat VSMC by increasing cPLA 2 or PLD activity.
Ang II has also been reported to increase Akt activity via transactivation of epidermal growth factor receptor (EGFR) in VSMC (Eguchi et al., 1999) . Cholesterol depletion that disrupts the structure of caveolae inhibits tyrosine phosphorylation of EGFR and subsequent activation of Akt induced by Ang II (Ushio-Fukai et al., 2001b) . EGFR overexpression or EGFR stimulation also increase PLD activity, and PLD associates with EGFR during its activation in fibroblasts (Slaaby et al., 1998; Lu et al., 2000; Kim et al., 2003) . Whether Ang II-induced Akt activation is mediated by transactivation of EGFR through PLD activation or via EGFRstimulated PLD activity in VSMC is not known.
EGFR transactivation by Ang II has also been shown to cause activation of p38 mitogen-activated protein kinase (MAPK) in VSMC (Eguchi et al., 2001 ). Moreover, expression of an active form of Akt increases p38 MAPK and its upstream kinase MKK3/6 activity in a follicular dendritic celllike cells (Lee et al., 2003) , whereas blockade of PI3K/Akt stimulates p38 MAPK-dependent apoptosis in endothelial cells (Gratton et al., 2001) . However, in some other cell types including VSMC, p38 MAPK has been reported to act upstream of Akt (Taniyama et al., 2004) , where p38 MAPK is constitutively associated with Akt and activates Akt through downstream MAPK-activated protein kinase-2 in VSMC (Taniyama et al., 2004) . p38 MAPK has also been shown to be upstream of PLD in VSMC (Min do et al., 2002) . These observations and the demonstration that in VSMC 1) activation of p38 MAPK by norepinephrine is mediated by metabolites of AA generated through activation of cPLA 2 (Kalyankrishna and Malik, 2003) and that lipoxygenase inhibitors cinnamyl-3,4-dihydroxy-␣-cyanocinnamate and baicalein attenuate p38 MAPK activation induced by Ang II in H295R adrenocortical cells (Natarajan et al., 2002) , and 2) Ang IIinduced PLD activation is dependent upon cPLA 2 activity (Parmentier et al., 2001b) have led us to hypothesize that Ang II-stimulated Akt phosphorylation in VSMC is mediated via transactivation of EGFR by a mechanism dependent upon PLD activation by p38 MAPK, which is stimulated by AA metabolites generated via cPLA 2 activation. The results of our study support this hypothesis and provide evidence that Ang II-induced Akt phosphorylation is mediated by the following sequence of activation of these signaling molecules: cPLA 2 3 AA metabolite(s)3p38 MAPK3 PLD3 PA3 EGFR transactivation3 Akt.
Materials and Methods

Materials
Chemicals were purchased commercially from the following sources: aprotinin, dithiothreitol, phenylmethylsulfonyl fluoride, sodium orthovanadate, leupeptin, HEPES, antipain, propranolol, 1-butanol, and 2-butanol from Sigma-Aldrich (St. Louis, MO); 4(3-chlorophenyamino)-6,7-dimethoxyquinazoline (AG1478) from Calbiochem (San Diego, CA); 1,6-bis-(cyclohexyloximinocarbonylamino)-hexane (RHC 80267) and 5,8,11,14-eicosatetraynoic acid (ETYA) from BIOMOL Research Laboratories (Plymouth Meeting, PA); 1,2-dioctanoyl-sn-glycerol-3-phosphate (diC8-PA) monosodium salt from Avanti Polar Lipids (Alabaster, AL); AA from Cayman Chemical (Ann Arbor, MI); 4-(4-flurophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole (SB202190) from Tocris Cookson Inc. (Ellisville, MO); human Ang II (H-Asp-Arg-Val-tyr-Ile-His-Pro-Phe-OH) and human EGF from Bachem Biosciences (King of Prussia, PA); anti-EGFR, anti-p38 MAPK, and anti-Akt1 (c-20) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti-phospho-tyr1068-EGFR, phospho-thr180/tyr182-p38 MAPK, and phospho-ser473-Akt antibodies from Cell Signaling Technology Inc. (Beverly, MA); anti-rabbit horseradish peroxidase-conjugated Ig serum from Amersham Biosciences UK, Ltd. (Little Chalfont, Buckinghamshire, UK); and anti-goat horseradish peroxidase-conjugated IgG (HϩL) from Vector Laboratories (Burlingame, CA). Pyrrolidine-1 was kindly provided by Dr. M. H. Gelb (University of Washington, Seattle, Washington). Anti-PLD 2 antibody was kindly supplied by Dr. Sylvain Bourgoin (Universite Laval, QC, Canada).
Methods
Isolation and Culture of VSMC. Male Sprague-Dawley rats (Harlan, Indianapolis, IN) weighing 250 to 350 g were anesthetized with 40 mg/kg sodium pentobarbital (Abbott Laboratories, Abbott Park, IL), and the thorax was opened. The thoracic aorta was excised and rapidly removed. VSMC were isolated, cultured, and maintained under 5% CO 2 in M199 medium with penicillin/streptomycin and 10% fetal bovine serum as described . VSMC between the fourth and tenth passages were made quiescent for 48 h in M199 containing 0.1% fetal bovine serum before exposure to various agents. VSMC were characterized using smooth muscle specific antiactin antibody. Cell viability was determined before and after each experimental intervention by measuring trypan blue exclusion.
Transfection of VSMC with Antisense Oligonucleotides. Phosphorothioate oligonucleotides directed against the translation initiation sites of rat cPLA 2 and PLD 2 were synthesized (Invitrogen, Carlsbad, CA). The sequences of oligonucleotides used in this study were: cPLA 2 sense, 5Ј-AZF GAT CCT TAT CAG CAC FZA-3Ј; cPLA 2 antisense, 5Ј-TFZ GTG CTG ATA AGG ATC ZFT-3Ј; and PLD 2 sense, 5Ј-AZE ACT GTA ACC CAG ACG EFC-3Ј; PLD 2 antisense, 5Ј-GZO CGT CTG GGT TAC AGT OFT-3Ј (FϭA-phosphorothioate, OϭC-phosphorothioate, EϭG-phosphorothioate, and ZϭT-phosphorothioate). VSMC, about 80% confluent, were transiently transfected with either sense or antisense oligonucleotides (200 nM) complexed with oligofectamine reagent according to the manufacturer's protocol (Invitrogen) and incubated for 6 h in the medium without antibiotics and serum. VSMC were maintained in M199 containing 0.1% fetal bovine serum in the presence of oligonucleotides. After 48 h, the cells were washed three times with Hanks' balanced salt solution and treated with Ang II (200 nM) or its vehicle.
Western Blot Analysis. The whole cell lysate from parental cells and transfected cells was prepared in lysis buffer (1% Igepal CA-630, 25 mM HEPES, pH 7.5, 50 mM NaCl, 50 mM NaF, 10 nM okadaic acid, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 10 g/ml antipain, 10 g/ml aprotinin, and 10 g/ml leupeptin), sonicated, centrifuged, and quantitated for protein content using the Bradford (1976) method. Equal amounts of protein (20ϳ80 g) were loaded onto SDS-polyacrylamide gel electrophoresis (20 mA/gel) and transferred onto nitrocellulose membrane (1 mA/mm 2 membrane). The blots were blocked, incubated with primary antibodies (1:1000) at 4°C overnight, and then incubated with their respective secondary antibodies conjugated with horseradish peroxidase for 1 h. Blots were developed with the ECL or ECL plus Western blotting detection kit (Amersham Biosciences Inc., Piscataway, NJ). The density of bands was measured using the NIH Image 1.6 program.
Preparation of siRNA and Transient Transfection of VSMC with Retroviral Gene Suppressor System. The primers with forward sequences 5Ј-TCGAG ACAGT AGTGG TTCTA CGTGCC gagtactg GGCAC GTAGA ACCAC TACTG TTTTTT-3Ј for cPLA 2 ; 5Ј-TCGAG CACAT GGAGC CAGAT GTGGTT gagtactg AACCA CATCT GGCTC CATGT GTTTTT-3Ј for PLD 2 ; and reverse 5Ј-CTAGA AAAAA CAGTA GTGGT TCTAC GTGCC cagtactc GGCAC GTAGA ACCAC TACTGTC-3Ј for cPLA 2 ; 5Ј-CTAGA AAAAC ACATG GAGCC AGATG TGGTT cagtactc AACCA CATCT GGCTC CAT-GTGC-3Ј for PLD 2 were synthesized by Integrated DNA Technologies (Coralville, IA). Forward and reverse primers were mixed and annealed at 95°C for 10 min and then gradually cooled to room temperature. The annealed oligonucleotides were inserted into linearized pSuppressorRetro viral vector using ready-to-go T4 DNA ligase kit (Amersham Biosciences Inc.). Competent DH5␣ cells (Invitrogen) were transformed with ligated plasmid DNA. After transformation, the colonies were amplified and purified using a miniprep purification kit (QIAGEN, Venlo, The Netherlands), and plasmid DNAs were sequenced using primer complementary to pSuppressorRetro viral vector. Plasmids with correct sequences were then amplified and purified with QIAGEN Maxi Plasmid DNA kit and used to transfect HEK 293 cells using the following procedures for amplification. HEK 293 cells were grown to ϳ30% to 50% confluence in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and penicillin/streptomycin. These cells were transfected with the plasmid DNAs (pECO packaging vector and pSuppressorRetro vector containing the cPLA 2 or PLD 2 siRNA insert) using the calcium phosphate precipitation method. The transfected cells were incubated for 3 to 4 h. Fresh medium was added and replaced on the second day. Virus was harvested by filtering the virus-containing supernatant. VSMC were made quiescent and infected with the viral supernatant in M199 containing 8 g/ml polybrene and 0.1% fetal bovine serum for 48 h before the stimulation. The infection efficiency was confirmed by ␤-galactosidase staining (Invitrogen) of cells infected with retrovirus containing control LacZ.
PLD Activity Assay. PLD activity was measured by the method described (Parmentier et al., 2001b) , which is based on the transphosphatidylation reaction between phosphatidic acid (PA) and ethanol that produces phosphatidylethanol (PtdEthanol). Briefly, VSMC transfected with cPLA 2 or PLD 2 sense or antisense oligonucleotides or VSMC infected with cPLA 2 siRNA or PLD 2 siRNA were radiolabeled with [ 3 H]oleic acid (1 Ci/ml) in M199 containing penicillin/streptomycin and 0.1% fetal bovine serum for 18 h. The labeled cells were preincubated with ethanol (200 mM) for 10 min. For VSMC treated with various inhibitors, the inhibitors were added into cells for 30 min before adding ethanol. Cells were then exposed to 200 nM Ang II for 15 min, and the reaction was terminated by adding ice-cold methanol/2 M HCl (9:1) and 0.25 M HCl. The lipids were extracted, separated by thin-layer chromatography as described (Parmentier et al., 2001b) , and visualized in iodine vapor. PtdEthanol was identified by the mobility of PtdEthanol standard and visualized with iodine vapor. Lanes containing radiolabeled PtdEthanol were moistened and scraped, and radioactivity was measured by scintillation spectroscopy. The data were expressed as the fractional 3 H-PtdEtoH of total 3 H total lipids. P38 MAPK Kinase Assay. p38 MAPK activity was determined by measuring the phosphorylation of its substrate ATF-2. Cell lysate (ϳ200 g of total protein) was immunoprecipitated with immobilized phospho-thr180/tyr182-p38 MAPK (monoclone; Cell Signaling Technology Inc.). Pellet was suspended and incubated 30 min in 50 l of kinase buffer (20 mM HEPES pH 7.6, 20 mM MgCl 2 , 20 mM ␤-glycerophosphate, and 2.0 mM dithiothreitol) containing 200 M radioactive cold ATP and 2 g of ATF-2 fusion protein at 37°C. Reaction was terminated with 25 l of 3ϫ SDS sample buffer subjected to SDS-polyacrylamide gel electrophoresis. p38 MAPK kinase activity was measured by probing the blots with phospho-ATF-2 antibody (1:1000, anti-rabbit).
Akt Kinase Assay. Akt activity was determined by measuring the phosphorylation of its substrate GSK-3␣ with Akt activity assay kit (Calbiochem). Cell lysate (ϳ200 g of total protein) was rotated with an anti-Akt antibody for 45 min at room temperature and then immunoprecipitated with protein A agarose beads for 1 h. Beads were washed two times with kinase extraction buffer and one time with kinase assay buffer supplied by kit. Washed beads were then suspended and incubated 3 h in 50 l of kinase assay buffer containing a 2-l GSK-3␣/ATP mixture at 30°C. The beads were spun down and discarded. Reaction of supernatant was terminated with 25 l of 3ϫ SDS sample buffer. Akt kinase activity was measured by probing with phospho-GSK-3␣ antibody (1:1000, anti-rabbit).
Results
Ang II-Stimulated Akt Phosphorylation Is Dependent on PLD Activity. Phosphorylation of Akt on threonine 308 in the kinase domain and serine 473 in the hydrophobic motif activates the kinase. Akt activity can be determined from the extent of phosphorylation of ser473. In cultured VSMC, Ang II promotes Akt phosphorylation through activation of AT 1 R (Takahashi et al., 1999) . In the present study, Ang II was used at a concentration of 200 nM, which has been shown to cause the maximal increase in Akt phosphorylation (Takahashi et al., 1999) . In rat VSMC, Ang II-stimulated Akt phosphorylation at ser473, which was inhibited by 1-butanol ( Fig. 1A ) a potent PLD inhibitor (Parmentier et al., 2001a,b) . However, its inactive analog 2-butanol did not affect the phosphorylation of Akt at the same concentration (Fig. 1A) . 1-Butanol, but not 2-butanol, inhibited the transphosphatidylation in the presence of ethanol catalyzed by PLD, an index of PLD activity (Fig. 1B ). These observations suggest that PLD is involved in Akt activation. Ang II-induced increase in PLD activity is mainly due to activation of the PLD 2 isoform in rabbit VSMC, rat renal microvascular smooth muscle cells, and A10 VSMC line (Shome et al., 2000; Andresen et al., 2001; Parmentier et al., 2001b) . To exclude possible nonspecific effects of these inhibitors on Akt activation, a retrovirus containing PLD 2 siRNA or PLD 2 antisense oligonucleotides were used to reduce the expression and activity of PLD 2 in the cultured VSMC. PLD 2 siRNA and antisense decreased PLD 2 protein expression and decreased Akt phosphorylation stimulated by Ang II without affecting Akt total protein expression (Fig. 1, C and D) , whereas VSMC infected with control retrovirus containing LacZ or transfected with PLD 2 sense oligonucleotide did not affect Ang II-induced Akt activation. PLD 2 siRNA, but not LacZ, attenuated Ang II- jpet.aspetjournals.org induced increase in PLD activity (Fig. 1E ), indicating that Akt phosphorylation elicited by Ang II is dependent on PLD 2 activation. Moreover, PLD 2 siRNA did not affect cPLA 2 protein level (data not shown). These data strongly suggest that Ang II-stimulated Akt phosphorylation is PLD 2 -dependent. The small G protein ADP-ribosylation factor (Arf) has been reported to regulate PLD 2 activity in A10 cells (Shome et al., 2000) . Brefeldin A, an Arf inhibitor, diminished Ang IIinduced PLD 2 activation in VSMC (Shome et al., 2000; Andresen et al., 2001) . In this study, the demonstration that brefeldin A decreased Ang II-induced Akt phosphorylation (Fig. 1F, lanes 1-4) further confirmed Ang II-stimulated Akt activity is dependent on PLD 2 activation.
Ang II-Induced PLD-Dependent Akt Phosphorylation Is Mediated by Phosphatidic Acid. PLD hydrolyzes phosphatidylcholine to PA and choline, and PA is metabolized by phosphatidate phosphohydrolase (PPH) into diacylglycerol (DAG) (Ueno et al., 2000; Parmentier et al., 2001a) . Whether PA or DAG causes Akt activation is not known. DAG can be phosphorylated to PA by DAG kinase (Billah et al., 1989; Ueno et al., 2000) . DAG kinase inhibitor II, which diminishes PA generation from DAG, attenuated Ang IIinduced Akt activation in VSMC (Fig. 2, A and B) . DAG kinase inhibitor II did not alter EGF-induced Akt phosphorylation, indicating that there is a selective contribution of PA to Ang II-but not EGF-induced Akt activation ( Fig. 2A) . Exogenous diC8-PA with short acyl chains that increase its water solubility and cell permeability also stimulated Akt phosphorylation (Fig. 2C ). These data indicate that PA generated by PLD activation is most likely involved in Ang II-induced Akt phosphorylation. DAG formed from PA by PPH causes the prolonged activation of protein kinase C and triggers other cell signaling pathways (Billah et al., 1989) , and it can also be hydrolyzed to AA by DAG lipase (Billah et al., 1989) . However, propranolol, a PPH inhibitor that reduces DAG production, and RHC 80267, a DAG lipase inhibitor that reduces AA release from DAG (Parmentier et al., 2001a) , did not diminish Ang II-induced Akt phosphorylation (Fig. 2D ). These data suggest that PA generated from PLD activation regulates Akt activation, whereas DAG or AA generated by PLD activation is not involved in Ang II-induced Akt phosphorylation in rat VSMC.
Ang II-Stimulated Akt Phosphorylation Is Mediated through PLD-Regulated EGFR Transactivation. Ang II signal transduction, including PI3K/Akt pathway (UshioFukai et al., 2001b) , has been reported to be mediated in part through EGFR transactivation (Eguchi et al., 1999 (Eguchi et al., , 2001 ). PI3K activation recruits Akt to the cell membrane and allows Akt phosphorylation by 3-phosphoinositide-dependent protein kinases (Shiojima and Walsh, 2002) . EGFR inhibitor AG1478 attenuated both Ang II-and EGF-induced Akt as well as EGFR phosphorylation, which suggests that Akt phosphorylation elicited by Ang II is mediated through EGFR transactivation in rat VSMC (Fig. 3A) . This is consistent with previous reports (Eguchi et al., 1999; Ushio-Fukai et al., 2001b) . Whether PLD-regulated Akt phosphorylation is mediated through EGFR transactivation by a sequential or a parallel pathway is not known and was investigated in the present study. 1-Butanol, an inhibitor of PLD activity, diminished Ang II-but not EGF-induced Akt phosphorylation (Fig.  3B) , suggesting that PLD acts upstream of EGFR and/or independent of EGFR transactivation. Since 1-butanol inhibited EGFR phosphorylation caused by Ang II (Fig. 3C ), it appears that PLD acts upstream of EGFR. PLD 2 siRNA, which decreased PLD protein expression, also reduced EGFR phosphorylation elicited by Ang II (Fig. 3D) . Moreover, brefeldin A reduced EGFR as well as Akt phosphorylation caused by Ang II without affecting EGF-stimulated Akt phosphorylation (Fig. 1F ). These data suggest that PLD-regulated Akt activation is mediated through EGFR transactivation. The effects of DAG kinase inhibitor II to reduce Ang II-but not EGF-induced Akt phosphorylation ( Fig. 2A ) and the effect of diC8-PA to promote EGFR phosphorylation (Fig. 2C ) indicate that PA is most likely the mediator of PLD-dependent EGFR transactivation.
Ang II-Stimulated PLD and Akt Activation and EGFR Phosphorylation Are Dependent upon cPLA 2 Activity. As shown in Fig. 1D , PLD 2 siRNA inhibited Ang II-induced Akt phosphorylation. PLD 2 siRNA also inhibited Akt activity as measured directly by the phosphorylation of its substrate, GSK-3␣ (Fig. 4) . Moreover, Ang II-induced Akt activation was also inhibited in VSMC infected with retrovirus containing cPLA 2 siRNA, but not by LacZ (Fig. 4) . cPLA 2 siRNA decreased cPLA 2 but not Akt protein expression. Furthermore, cPLA 2 siRNA did not significantly decrease PLD 2 protein expression (data not shown). These observations indicate that Ang II-stimulated Akt phosphorylation is also dependent upon cPLA 2 activation. Since both cPLA 2 and PLD are involved in Ang II stimulation of Akt and since PLD activity is dependent on cPLA 2 stimulation in VSMC (Parmentier et al., 2001b) , we determined the relationship between cPLA 2 and PLD in Akt phosphorylation. cPLA 2 antisense but not sense oligonucleotide or cPLA 2 siRNA but not LacZ control virus attenuated Ang II-stimulated PLD activity (Fig. 5, A and B) . Moreover, ETYA, an inhibitor of metabolism of AA that is generated from cPLA 2 activation, also (Fig. 5C ). Since 1-butanol and PLD 2 siRNA inhibited EGFR transactivation, we examined EGFR phosphorylation by Ang II in cells infected with retroviral vectors containing cPLA 2 siRNA and LacZ. EGFR phosphorylation elicited by Ang II was inhibited by cPLA 2 siRNA but not by LacZ (Fig. 3D) . Moreover, ETYA inhibited both Ang IIand AA-stimulated phosphorylation of EGFR (Fig. 6, A and  B) , suggesting that the metabolites of AA generated through cPLA 2 activation are also involved in Ang II-induced EGFR transactivation that is mediated by PLD activation.
Ang II-Stimulated, cPLA 2 -Dependent PLD Activation Leading to EGFR Transactivation and Akt Phosphorylation Is Mediated by p38 MAPK. Ang II causes p38 MAPK activation in VSMC, which has been also been implicated in Akt activation (Taniyama et al., 2004) . However, the relationship between p38 MAPK, PLD, EGFR, and Akt in VSMC has not yet been established. Since 1) p38 MAPK (Kalyankrishna and Malik, 2003) and PLD (Parmentier et al., 2001a,b) activation in rabbit VSMC has been shown to be mediated by metabolites of AA derived via lipoxygenase and P450, consequent to cPLA 2 activation, 2) EGFR inhibitor AG1478 suppresses MAPK activation induced by AA in a renal tubular cell line overexpressing the rat nonglycosylated ␣2-adrenergic receptor (Cussac et al., 2002) , and 3) p38 MAPK mediates PLD activation in VSMC (Min do et al., 2002), we determined the possible involvement of p38 MAPK in Ang II-regulated PLD activation, EGFR transactivation, and Akt phosphorylation in rat VSMC. Ang II increased p38 MAPK activity in rat VSMC (Fig. 7A) , and SB202190, a selective p38 MAPK inhibitor (Fatima et al., 2001) , reduced PLD activation elicited by Ang II (Fig. 7B) . SB202190 also attenuated EGFR and Akt phosphorylation elicited by both Ang II and AA (Fig. 7, C and D) . These data suggest that p38 MAPK acts upstream of PLD-dependent EGFR transactivation in Akt phosphorylation elicited by Ang II. The inhibitory effect of SB202190 on AA-stimulated EGFR and Akt phosphorylation implicates p38 MAPK in cPLA 2 -dependent PLD activation. The selective cPLA 2 inhibitor pyrrolidine-1 also reduced p38 MAPK phosphorylation induced by Ang II (Fig. 8A) , as did cPLA 2 siRNA but not its LacZ control virus (Fig. 8B) . We also measured p38 MAPK activity by examining the phosphorylation of its substrate ATF-2. cPLA 2 siRNA inhibited ATF phosphorylation elicited by Ang II (Fig. 8C) . Because EGF stimulates p38 MAPK and cPLA 2 in VSMC Eguchi et al., 2001 ), SB202190 and ETYA were used to determine their effect on EGF-stimulated Akt and EGFR phosphorylation. SB202190 did not inhibit EGF-stimulated Akt phosphorylation, although it significantly reduced Akt phosphorylation elicited by both Ang II and AA (Fig. 9A) . ETYA, which inhibited Ang II-and AA-induced EGFR phosphorylation (Fig. 6) , did not inhibit EGF-stimulated EGFR phosphorylation (Fig. 9B) . These data further support our findings that p38 MAPK and AA metabolite(s) generated by cPLA 2 activation act upstream of EGFR.
Discussion
The present study demonstrates that in rat VSMC Ang IIinduced Akt activation is mediated by PLD-regulated EGFR transactivation consequent to activation of p38 MAPK by me- tabolite(s) of AA generated by increased cPLA 2 activity (Ang II3cPLA 2 3 AA metabolite(s)3p38 MAPK3 PLD 2 3 PA3 EGFR3Akt). This conclusion is based on our demonstration that Ang II-induced increase in Akt activity measured by its phosphorylation at serine 473 was inhibited by 1-butanol, which reduced PLD activity. PLD activity is regulated by the small G protein Arf (Shome et al., 2000; Andresen et al., 2001) . Brefeldin A, an inhibitor of Arf, inhibits Ang II-induced PLD 2 activity in renal microvascular smooth muscle cells and A10 cells (Shome et al., 2000; Andresen et al., 2001) . That brefeldin A also diminished Akt phosphorylation induced by Ang II supports our contention that PLD is involved in Akt activation. The selectivity of 1-butanol and brefeldin A to inhibit Ang II-induced Akt phosphorylation was indicated by our finding that these agents did not reduce Akt phosphorylation elicited by EGF. That Ang II-induced Akt phosphorylation is dependent upon PLD activity was further indicated by our demonstration that in VSMC, in which the PLD 2 isoform predominates (Shome et al., 2000; Andresen et al., 2001; Parmentier et al., 2001b) , infection of the cells with retrovirus containing PLD 2 siRNA inhibited Akt phosphorylation and PLD activation elicited by Ang II. Furthermore, PLD 2 antisense oligonucleotide reduced Akt phosphorylation stimulated by Ang II. From these observations, it follows that Ang II-induced Akt phosphorylation is dependent on PLD 2 activation in rat VSMC. Lysophosphatidic acid and sphingosine-1 phosphate have also been reported to activate protein translation via PI3K/Akt by a mechanism de- jpet.aspetjournals.org pendent on PLD (Banno et al., 2001; Kam and Exton, 2004) . However, in adrenocorticol carcinoma cells, Ang II-induced PLD activation is attenuated by PI3K/Akt inhibitors, suggesting that Akt acts upstream of PLD in these cells (Zheng and Bollag, 2003) . From these observations, it follows that the contribution of PLD in Akt activation may be dependent upon the stimulus and the cell type. Activation of PLD promotes hydrolysis of phosphatidylcholine to PA, which is metabolized by PPH into DAG, that in turn can be phosphorylated by DAG kinase to reform PA or hydrolyzed by DAG lipase to generate AA (Ueno et al., 2000; Parmentier et al., 2001a) . One or more of these products could contribute to Akt phosphorylation caused by Ang II. Our findings that the DAG kinase inhibitor II diminished Ang II induced and the cell permeable diC8-PA increased Akt phosphorylation suggest that PA generated by PLD activation mediates Akt phosphorylation in VSMC. Accumulation of PA by overexpression with exogenous Streptomyces chromofuscus PLD also results in an increase in PI3K activity and the phosphorylation of Akt in Chinese hamster ovary cells overexpressing EDG 3 (Banno et al., 2001) . The selectivity of the DAG kinase II inhibitor to decrease Ang II-induced Akt activation was indicated by our observation that this agent did not alter EGF-induced Akt activation. DAG or AA generated by PLD activation does not appear to be involved in Ang II-induced PLD activation because propranolol, an inhibitor of PPH, and RHC 80267, a DAG lipase inhibitor, which decrease DAG and AA generation respectively without affecting PLD activity (Parmentier et al., 2001a) , failed to alter Akt phosphorylation caused by Ang II in VSMC. Although activation of both PLD and cPLA 2 releases AA, it appears that AA and its metabolites generated consequent to the activation of cPLA 2 but not PLD promotes Akt phosphorylation. This could be due to compartmentalization of AA or the quantity of AA generated by these lipases.
Ang II causes transactivation of EGFR by releasing soluble heparin binding EGF through activation of metalloproteases (Eguchi et al., 2001) . EGFR activation by EGF also promotes Akt activation (Burgering and Coffer, 1995) , and Ang II has been shown to cause Akt activation via EGFR transactivation in VSMC (Eguchi et al., 1999; Ushio-Fukai et al., 2001b) . In our study, an EGFR tyrosine kinase inhibitor AG1478 also diminished Ang II-stimulated Akt phosphorylation. However, in addition to metalloproteinase-sensitive EGFR transactivation, other molecules including reactive oxygen species and Ca 2ϩ / calmodulin have also been implicated in Ang II-induced tyrosine phosphorylation/transactivation of the EGFR (Murasawa et al., 1998; Ushio-Fukai et al., 2001a) . Expression of EGFR or EGFR activation with EGF also increases PLD activity in some cell types (Slaaby et al., 1998; Lu et al., 2000; Kim et al., 2003) . PLD 2 has been shown to bind to EGFR in HEK 293 cells transiently transfected with mouse PLD 2 , where EGF stimulates PLD 2 tyrosine phosphorylation at residue 11 (Slaaby et al., 1998) . This raises the possibility that EGFR transactivation-dependent Akt activation is linked to Ang IIstimulated PLD activity. Our demonstration that the inhibitors of PLD activity 1-butanol, brefeldin A, and PLD 2 siRNA, which diminished Akt phosphorylation, also attenuated EGFR phosphorylation suggests that PLD 2 mediates EGFR transactivation, which in turn promotes Akt phosphorylation in response to Ang II. That 1-butanol and brefeldin A did not reduce Akt phosphorylation caused by EGF suggests that PLD acts upstream of EGFR in rat VSMC, although PLD activity increases when EGFR is activated (Lu et al., 2000) . Our study suggests that PA generated by PLD 2 activation is involved in EGFR transactivation.
AA metabolites generated consequent to activation of cPLA 2 in rabbit VSMC mediates the Ang II-induced increase in PLD activity (Parmentier et al., 2001a) . Moreover, PLA 2 inhibition attenuates and AA stimulates Akt phosphorylation in mesangial cells (Gorin et al., 2001 ). These observations and our findings that cPLA 2 antisense and siRNA and the inhibitor of AA metabolism ETYA attenuated PLD activity and EGFR phosphorylation elicited by Ang II suggest that metabolites of AA generated via activation of cPLA 2 by in- Fig. 8 . p38 MAPK activation by Ang II is dependent on the cPLA 2 activity. A, cPLA 2 -specific inhibitor pyrrolidine-1 attenuated Ang II-stimulated p38 MAPK phosphorylation. Quiescent VSMC were pretreated with pyrrolidine-1 (100 nM) for 30 min before treatment with Ang II (200 nM) for 5 min. Equal protein loadings of each lysate sample were immunoblotted with antibody specific for phospho-thr180/tyr182-p38 and p38 MAPK protein. B, cPLA 2 siRNA inhibited Ang II-stimulated p38 MAPK phosphorylation. VSMC were infected with retrovirus containing LacZ or cPLA 2 siRNA for 48 h before exposure to 200 nM Ang II for 5 min. Equal protein loadings of each lysate sample were immunoblotted with antibody specific for phospho-thr180/tyr182-p38 MAPK and p38 MAPK. C, cPLA 2 siRNA inhibited Ang II-stimulated p38 MAPK kinase activity. VSMC were infected with retrovirus containing LacZ or cPLA 2 siRNA for 48 h before exposure to 200 nM Ang II for 5 min. Equal amount of protein from each lysate sample was immunoprecipitated with immobilized phosphothr180/tyr182-p38 MAPK antibody. p38 MAPK kinase activity was measured by the phosphorylation of the substrate ATF-fusion protein. The blots shown in each panel are representative of three different experiments. The mechanism by which AA metabolites increase PLD activity in VSMC is not known. AA and/or its metabolites (hydroxyeicosatetraenoic acids) generated via lipoxygenase and/or P450 have been shown to increase p38 MAPK activity in VSMC (Kalyankrishna and Malik, 2003) . In the present study, cPLA 2 siRNA decreased both p38 MAPK phosphorylation and activation elicited by Ang II. Moreover, the cPLA 2 -specific inhibitor pyrrolidin-1 also decreased the phosphorylation of p38 MAPK. PLD activation by norepinephrine in VSMC is partially inhibited by either a MEK1 inhibitor (PD98059) (Muthalif et al., 2000; Parmentier et al., 2001b) or a p38 MAP kinase inhibitor (SB203580) (Min do et al., 2002) , although SB203580 did not inhibit PLD activity in endothelial cells (Natarajan et al., 2001) . However, Ang II-stimulated PLD activity has been reported to be independent of extracellular signal-regulated kinase 1/2 MAPK in VSMC derived from hypertensive rats (Wilkie et al., 1996) . Moreover, the MEK-1/2 inhibitor U0126 also failed to inhibit Ang IIinduced PLD-regulated Akt phosphorylation (Supplemental Data). MAPK-activated protein kinase-2, a kinase regulated by p38 MAPK in VSMC, stimulates the phosphorylation of Akt (Taniyama et al., 2004) . Our finding that the specific p38 MAP kinase inhibitor SB202190 (Fatima et al., 2001 ) attenuated PLD activity and Akt phosphorylation elicited by Ang II or AA, suggests that p38 MAPK mediates cPLA 2 -dependent activation of PLD and consequently EGFR transactivation and Akt phosphorylation. Ang II has also been shown to cause activation of p38 MAPK through EGFR transactivation in VSMC (Eguchi et al., 2001 ). However, p38 MAPK activated via EGFR transactivation does not appear to be involved in Ang II-induced Akt phosphorylation because p38 MAPK inhibitor SB202190 did not decrease EGF-induced Akt phosphorylation. From these observations, it follows that in rat VSMC p38 MAPK acts upstream of EGFR and mediates Ang II-induced Akt activation by stimulating PLDdependent EGFR transactivation.
In conclusion, our study demonstrates that Ang II stimulates PLD activity in rat VSMC via p38 MAPK activated by one or more AA metabolite(s) generated consequent to cPLA 2 activation. The increased PLD activity by generating PA promotes EGFR transactivation, which in turn causes phosphorylation of Akt (Fig. 10) . Further studies are required to elucidate the mechanism by which AA metabolite(s) cause activation of p38 MAPK and PA promotes EGFR transactivation. In view of the demonstration that 1) AA metabolites derived via lipoxygenase and cytochrome P450 activate p38 MAPK in rabbit VSMC (Kalyankrishna and Malik, 2003) and 2) the AA metabolite of lipoxygenase 12-hydroxyeicosatetraenoic acid increase the activity of small G protein Rac, which is an upstream activator of p38 MAPK (Wen et al., 1996) , it is possible that AA metabolite(s) generated via lipoxygenase and/or P450 by activating Rac increase p38 MAPK activity, which in turn increases PLD activity in rat VSMC (Fig. 10) . 
